Sage Journals: Discover world-class research

Open access

Research article

First published 2021

Afatinib as first-line treatment in patients with EGFR -mutated non-small cell lung cancer in routine clinical practice

Wolfgang M. Brückl, Martin Reck, Frank Griesinger [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2024

Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam

Van Luan Pham, Tuan Anh Le, Cam Phuong Pham [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025-09

Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I

Thanh Ha Vu, Hoa Thai Thi Nguyen, To Van Ta [...]

Cancer Control

Open access

Review article

First published 2018

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

Biagio Ricciuti, Sara Baglivo, Andrea De Giglio [...]

Therapeutic Advances in Respiratory Disease

Open access

Review article

First published 2019

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Keunchil Park, Darren Wan-Teck Lim, Isamu Okamoto [...]

Therapeutic Advances in Medical Oncology

Free access

Review article

First published 2016-6

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

E-E Ke, Yi-Long Wu

Therapeutic Advances in Respiratory Disease

Open access

Research article

First published 2025

Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam

Van Luan Pham, Cam Phuong Pham, Thi Thai Hoa Nguyen [...]

Therapeutic Advances in Respiratory Disease

Retricted access

Case report

First published 2018-12

Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences

Francesca Mazzoni, Paolo Petreni, Marco Perna [...]

Tumori Journal

Open access

Research article

First published 2022

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu [...]

Therapeutic Advances in Medical Oncology

Open access

Review article

First published 2020-9

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

R Donald Harvey, Val R Adams, Tyler Beardslee [...]

Journal of Oncology Pharmacy Practice

Search results